Earnings Call
May 6, 2026
Q1 FY2026
EPS Estimate
4.80
EPS Actual
4.08
Post-Earnings Close
$252.74
Earnings Reaction
-17.4%
Cencora opened fiscal 2026 with adjusted diluted EPS of $4.08, up 9% year-over-year, on consolidated revenue of $85.9 billion, a 5.5% increase that came in well ahead of the $81.1 billion consensus estimate. The headline numbers, however, are secondary to the strategic event that defined the quarter: the completion of the OneOncology acquisition, announced on the morning of the earnings call. With that deal closed, Cencora now controls 92% of one of the largest community oncology MSO platforms in the United States, pairing it with Retina Consultants of America, acquired just over a year ago, to form a pharmaceutical-centric MSO platform that management views as a structural competitive differentiator in specialty pharmaceuticals.
Report generated on May 5, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full COR analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.